| Original language | English (US) |
|---|---|
| Pages (from-to) | 344-345 |
| Number of pages | 2 |
| Journal | Annals of Allergy, Asthma and Immunology |
| Volume | 128 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2022 |
Funding
Funding: This study is funded by the Edelstein Family Chair of Pediatric Allergy-Immunology. The authors acknowledge Nicole Meiklejohn for her assistance in preparing this manuscript. Disclosures: Dr Leung is an employee at the National Jewish Health and has consulted with Incyte Corporation, Leo Pharma, Sanofi-Genzyme Pharma, and Regeneron Pharmaceuticals. Dr Paller is an employee at Northwestern; reports receiving research funds from AbbVie, Eli Lilly, Incyte, and Regeneron; and has consulted with AbbVie, Almirall, Arcutis, Arena, BiomX, Bristol Myers Squibb, Catawba, Eli Lilly, Gilead, Incyte, Janssen, Leo, Novartis, Pfizer, RAPT, Regeneron, Sanofi/Genzyme, and Seanergy. Dr Guttman-Yassky is an employee of Mount Sinai; reports receiving research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boerhinger-Ingelhiem, Cara Therapeutics, Celgene, Eli Lilly, Galderma, Glenmark/Ichnos Sciences, Innovaderm, Janssen, KAO, Kiniksa, Kyowa Kirin, Leo Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron Pharmaceuticals, and UCB; and is a consultant for AbbVie, Almirall, Amgen, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boerhinger-Ingelhiem, Bristol-Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, Leo Pharma, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB, and Ventyx Biosciences. Funding: This study is funded by the Edelstein Family Chair of Pediatric Allergy-Immunology.
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pulmonary and Respiratory Medicine